Rabefour 20 mg (Capsule (Enteric Coated))
Medicine Details
| Category | Details |
|---|---|
| Generic | Rabeprazole sodium |
| Company | Albion laboratories limited |
Title
Rabefour 20 mg Capsule
Categories
- Medicine
- Pharmaceutical
- Gastrointestinal
Description
Rabefour Gastro-resistant tablets are indicated for the treatment of active duodenal ulcer, active benign gastric ulcer, symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD), Zollinger-Ellison Syndrome, GERD long-term management, and in combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease.
Dosage
20 mg once daily in the morning for active duodenal ulcer and active benign gastric ulcer, 20 mg once daily for four to eight weeks for erosive or ulcerative GERD, and other specific dosages for different conditions as per the instructions.
Pharmacology
Suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell, characterized as a gastric proton-pump inhibitor.
Interaction
Potential interaction with compounds whose absorption is pH dependent. Co-administration with certain drugs may require dosage adjustment. No interaction with liquid antacids. Not recommended to be co-administered with atazanavir.
Contraindications
Contra-indicated in individuals with hypersensitivity to the active substance or excipients, and in pregnant or breastfeeding women.
Side effects
Well-tolerated in both short-term and long-term studies, with possible side effects such as headache, diarrhea, abdominal pain, vomiting, constipation, dry mouth, increased or decreased appetite, muscle pain, drowsiness, and dizziness.
Pregnancy and lactation
US FDA pregnancy category 'C'. No adequate and well-controlled studies in pregnant women. Likely to be excreted in human milk, hence a decision should be made whether to discontinue nursing or the drug, considering its importance to the mother.
Precautions and warnings
- Symptomatic response to therapy does not exclude the presence of gastric or esophageal malignancy.
- Patients on long-term treatment should be under regular surveillance.
- May modestly increase the risk of hip, wrist and spine fracture, particularly in the elderly or in presence of other risk factors.
- A risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded.
- Hypomagnesaemia, influence on vitamin B12 absorption, subacute cutaneous lupus erythematosus, and interference with laboratory tests should be considered.
- Not recommended for use in children due to a lack of data on safety and efficacy.
Overdose effects
Maximum established exposure not exceeding 60 mg twice daily, or 160 mg once daily. Effects are generally minimal and reversible without further medical intervention. No specific antidote is known.
Therapeutic class
Proton Pump Inhibitor
Storage conditions
Store below 30°C temperature, away from light & moisture, and out of the reach of children.
Chemical structure
- Molecular Formula: C18H21N3O3S
- Chemical Structure: Image of chemical structure provided.
Common questions and answers
- What is Rabefour 20 mg Capsule?: A proton pump inhibitor that suppresses gastric acid secretion.
- What is Rabefour 20 mg Capsule used for?: Treatment of Duodenal ulcer, Gastric ulcer, GERD, Zollinger-Ellison Syndrome, Helicobacter pylori eradication.
- What are the side effects of Rabefour 20 mg Capsule?: Common side effects include diarrhea, constipation, nausea, vomiting, headache, dizziness, rash, dry mouth. Serious side effects are rare but can include kidney problems, liver damage, and bone fractures.
- How should I take Rabefour 20 mg Capsule?: Take with food, as prescribed. Do not exceed the prescribed dose.
- Can I take Rabefour 20 mg Capsule while pregnant or breastfeeding?: Not recommended during pregnancy or breastfeeding. Discuss risks and benefits with a doctor.
- What should I do if I overdose on Rabefour 20 mg Capsule?: Seek immediate medical attention. Overdose symptoms include drowsiness, confusion, and seizures.
- How long should I take Rabefour 20 mg Capsule?: Length of treatment depends on the specific condition being treated.
- Is there anything else I should know about Rabefour 20 mg Capsule?: Can cause dry mouth. Long-term use can lead to weak bones. Consult a doctor for specific concerns.